A step closer toward therapies for p63-related disorders

References

• Shalom-Feuerstein R, Serror L, Aberdam E, Müller FJ, van Bokhoven H, Wiman KG, et al. Impaired epithelial differentiation of induced pluripotent stem cells from ectodermal dysplasia-related patients is rescued by the small compound APR-246/PRIMA-1MET. Proc Natl Acad Sci U S A 2013; 110:2152 - 6; http://dx.doi.org/10.1073/pnas.1201753109; PMID: 23355677
   PubMed Web of Science ®Google Scholar
• Shen J, van den Bogaard EH, Kouwenhoven EN, Bykov VJ, Rinne T, Zhang Q, et al. APR-246/PRIMA-1MET rescues epidermal differentiation in skin keratinocytes derived from EEC syndrome patients with p63 mutations. Proc Natl Acad Sci U S A 2013; 110:2157 - 62; http://dx.doi.org/10.1073/pnas.1201993110; PMID: 23355676
   PubMed Web of Science ®Google Scholar
• Soussi T. p53 alterations in human cancer: more questions than answers. Oncogene 2007; 26:2145 - 56; http://dx.doi.org/10.1038/sj.onc.1210280; PMID: 17401423
   PubMed Web of Science ®Google Scholar
• Soussi T, Wiman KG. Shaping genetic alterations in human cancer: the p53 mutation paradigm. Cancer Cell 2007; 12:303 - 12; http://dx.doi.org/10.1016/j.ccr.2007.10.001; PMID: 17936556
   PubMed Web of Science ®Google Scholar
• Rinne T, Brunner HG, van Bokhoven H. p63-associated disorders. Cell Cycle 2007; 6:262 - 8; http://dx.doi.org/10.4161/cc.6.3.3796; PMID: 17224651
   PubMed Web of Science ®Google Scholar
• Di Iorio E, Kaye SB, Ponzin D, Barbaro V, Ferrari S, Böhm E, et al. Limbal stem cell deficiency and ocular phenotype in ectrodactyly-ectodermal dysplasia-clefting syndrome caused by p63 mutations. Ophthalmology 2012; 119:74 - 83; http://dx.doi.org/10.1016/j.ophtha.2011.06.044; PMID: 21959367
   PubMed Web of Science ®Google Scholar
• Lehmann S, Bykov VJ, Ali D, Andrén O, Cherif H, Tidefelt U, et al. Targeting p53 in vivo: a first-in-human study with p53-targeting compound APR-246 in refractory hematologic malignancies and prostate cancer. J Clin Oncol 2012; 30:3633 - 9; http://dx.doi.org/10.1200/JCO.2011.40.7783; PMID: 22965953
   PubMed Web of Science ®Google Scholar
• Rouleau M, Medawar A, Hamon L, Shivtiel S, Wolchinsky Z, Zhou H, et al. TAp63 is important for cardiac differentiation of embryonic stem cells and heart development. Stem Cells 2011; 29:1672 - 83; http://dx.doi.org/10.1002/stem.723; PMID: 21898690
   PubMed Web of Science ®Google Scholar
• Candi E, Rufini A, Terrinoni A, Giamboi-Miraglia A, Lena AM, Mantovani R, et al. DeltaNp63 regulates thymic development through enhanced expression of FgfR2 and Jag2. Proc Natl Acad Sci U S A 2007; 104:11999 - 2004; http://dx.doi.org/10.1073/pnas.0703458104; PMID: 17626181
   PubMed Web of Science ®Google Scholar
• Yang A, Schweitzer R, Sun D, Kaghad M, Walker N, Bronson RT, et al. p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development. Nature 1999; 398:714 - 8; http://dx.doi.org/10.1038/19539; PMID: 10227294
   PubMed Web of Science ®Google Scholar
• Mills AA, Zheng B, Wang XJ, Vogel H, Roop DR, Bradley A. p63 is a p53 homologue required for limb and epidermal morphogenesis. Nature 1999; 398:708 - 13; http://dx.doi.org/10.1038/19531; PMID: 10227293
   PubMed Web of Science ®Google Scholar
• Lo Iacono N, Mantero S, Chiarelli A, Garcia E, Mills AA, Morasso MI, et al. Regulation of Dlx5 and Dlx6 gene expression by p63 is involved in EEC and SHFM congenital limb defects. Development 2008; 135:1377 - 88; http://dx.doi.org/10.1242/dev.011759; PMID: 18326838
   PubMed Web of Science ®Google Scholar
• Rinne T, Hamel B, van Bokhoven H, Brunner HG. Pattern of p63 mutations and their phenotypes--update. Am J Med Genet A 2006; 140:1396 - 406; http://dx.doi.org/10.1002/ajmg.a.31271; PMID: 16691622
   PubMed Web of Science ®Google Scholar
• Di Iorio E, Barbaro V, Ruzza A, Ponzin D, Pellegrini G, De Luca M. Isoforms of DeltaNp63 and the migration of ocular limbal cells in human corneal regeneration. Proc Natl Acad Sci U S A 2005; 102:9523 - 8; http://dx.doi.org/10.1073/pnas.0503437102; PMID: 15983386
   PubMed Web of Science ®Google Scholar
• Wiman KG. Pharmacological reactivation of mutant p53: from protein structure to the cancer patient. Oncogene 2010; 29:4245 - 52; http://dx.doi.org/10.1038/onc.2010.188; PMID: 20498645
   PubMed Web of Science ®Google Scholar
• Cho Y, Gorina S, Jeffrey PD, Pavletich NP. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science 1994; 265:346 - 55; http://dx.doi.org/10.1126/science.8023157; PMID: 8023157
   PubMed Web of Science ®Google Scholar
• Rökaeus N, Shen J, Eckhardt I, Bykov VJ, Wiman KG, Wilhelm MT. PRIMA-1(MET)/APR-246 targets mutant forms of p53 family members p63 and p73. Oncogene 2010; 29:6442 - 51; http://dx.doi.org/10.1038/onc.2010.382; PMID: 20818419
   PubMed Web of Science ®Google Scholar
• Weinmann L, Wischhusen J, Demma MJ, Naumann U, Roth P, Dasmahapatra B, et al. A novel p53 rescue compound induces p53-dependent growth arrest and sensitises glioma cells to Apo2L/TRAIL-induced apoptosis. Cell Death Differ 2008; 15:718 - 29; http://dx.doi.org/10.1038/sj.cdd.4402301; PMID: 18202704
   PubMed Web of Science ®Google Scholar
• Shalom-Feuerstein R, Lena AM, Zhou H, De La Forest Divonne S, Van Bokhoven H, Candi E, et al. ΔNp63 is an ectodermal gatekeeper of epidermal morphogenesis. Cell Death Differ 2011; 18:887 - 96; http://dx.doi.org/10.1038/cdd.2010.159; PMID: 21127502
   PubMed Web of Science ®Google Scholar
• Crum CP, McKeon FD. p63 in epithelial survival, germ cell surveillance, and neoplasia. Annu Rev Pathol 2010; 5:349 - 71; http://dx.doi.org/10.1146/annurev-pathol-121808-102117; PMID: 20078223
   PubMed Web of Science ®Google Scholar
• Shalom-Feuerstein R, Serror L, De La Forest Divonne S, Petit I, Aberdam E, Camargo L, et al. Pluripotent stem cell model reveals essential roles for miR-450b-5p and miR-184 in embryonic corneal lineage specification. Stem Cells 2012; 30:898 - 909; http://dx.doi.org/10.1002/stem.1068; PMID: 22367714
   PubMed Web of Science ®Google Scholar